Tin tức & Cập nhật

Treatment with deucravacitinib demonstrates its superiority to placebo across several endpoints in patients with psoriatic arthritis (PsA) at week 16, according to the phase III POETYK PsA-2 study. Clinical responses have also persisted for up to a year.

Ritlecitinib 50 mg demonstrates clinically meaningful efficacy up to 36 months in individuals with alopecia areata (AA) in the phase IIb/III ALLEGRO and ongoing phase III ALLEGRO-LT trials.

Findings from the phase III ROCKET-SHUTTLE trial support the treatment potential of rocatinlimab for atopic dermatitis (AD).

Treatment with bimekizumab for 4 years results in satisfactory levels of clinical and health-related quality of life responses, reports a study. The majority of patients with moderate-to-severe plaque psoriasis achieve near-complete skin clearance, while nearly two-thirds have complete skin clearance.

Individuals with psoriasis may benefit from an increased level of serum 25-hydroxivitamin D (25[OH]D), which has shown an association with a reduced risk of overall mortality and cardiovascular disease (CVD) in a recent study.

A cell harvesting device that prepares autologous skin cell suspension (ASCS) offers a simple yet accessible technique for melanocyte transplantation in patients with vitiligo, a study has shown.